In recent years, reduced-intensity conditioning (RIC) regimens before allogeneic stem cell transplantation (SCT) are increasingly used in patients not eligible for conventional conditioning. We did a retrospective, multicenter analysis to assess the feasibility of conditioning with fludarabine and treosulfan before allogeneic SCT in multiple myeloma patients. Thirty-four patients with a median age of 51.5 years were included in the analysis. All patients underwent myeloablation after conditioning followed by stable engraftment, and 29 of 31 evaluable patients (94%) showed early complete hematopoietic chimerism. Non-hematological toxicities were limited and encompassed mainly fever in neutropenia and infections. Grade II-IV acute and chronic graft-versushost disease was observed in 33 and 39%, respectively. With a median follow-up of 708 days (range 60-1729 days), the median progression-free survival was 180 days. The treatment-related mortality was 10% on day 100 and 25% after 1 year. The median overall survival has not yet been reached. Our data indicate that conditioning with fludarabine and treosulfan before allogeneic SCT is feasible in intensively pretreated multiple myeloma patients and leads to stable engraftment and complete hematopoietic chimerism. Randomized trials are warranted to determine if this approach might be incorporated in an algorithm of multiple myeloma treatment.
Introduction
Allogeneic stem cell transplantation (SCT) was introduced as the only potentially curative therapy for multiple myeloma in the early 1980s. 1 This approach leads to a complete response (CR) in a significant proportion of patients, even in those who relapsed after autologous stem cell transplantation (ASCT) or showed progressive disease (PD) before allogeneic SCT. 2, 3 However, allogeneic SCT with conventional conditioning is limited to younger patients who lack major comorbidity. To make it applicable in elderly patients and minimize treatment-related mortality (TRM) in younger ones, reduced-intensity conditioning (RIC) regimens have been developed in recent years. [4] [5] [6] [7] These regimens are based predominantly on the graft-versus-myeloma effect and to a lesser extent on cytotoxicity of the conditioning agents. [8] [9] The nucleoside analogue fludarabine has already been incorporated into a variety of reduced-intensity or nonmyeloablative conditioning regimens. [10] [11] [12] The substance is characterized by high activity against lymphoid neoplasms and has a favorable toxicity profile. 13 Its immunosuppressive effects, particularly on T-cell activity, makes the substance suitable as part of a RIC regimen before allogeneic SCT. In multiple myeloma, fludarabine is frequently used in combination with either busulfan, melphalan, cyclophosphamide or low-dose total body irradiation (TBI) before allogeneic SCT. 5, 14, 15 Treosulfan (L-threitol-1,4-bis-methanesulfonate; dihydroxybusulfan, NSC 39069) is a prodrug of a bifunctional alkylating cytotoxic agent and has been evaluated in the therapy of solid tumors, including ovarian cancer and uveal melanoma. 16, 17 A pronounced in vitro cytotoxicity of treosulfan was demonstrated in multiple myeloma and lymphoma cell lines of human origin. In multiple myeloma cell lines, the cytotoxicity of treosulfan was equal or superior to that of melphalan. 18, 19 Its organ toxicities are limited, even near the maximum tolerable dose of 47 g/ m 2 . 20, 21 The substance has very recently been introduced in the allogeneic stem cell setting in combination with fludarabine or cyclophosphamide. First clinical experiences demonstrated the feasibility and efficacy of this novel conditioning regimen. 22, 23 Despite these favorable data, fludarabine-/treosulfanbased conditioning before allogeneic SCT has not yet been systematically investigated in multiple myeloma. Compared to melphalan and busulfan, the other two common conditioning agents in multiple myeloma therapy, treosulfan might have the advantage of less nephro-and cardiotoxicity than the former and less liver and lung toxicity than the latter. 12, 24 Moreover, a switch of the alkylating agent may have the further advantage of increased efficacy, because the majority of multiple myeloma patients receive melphalan as upfront therapy.
To assess the feasibility of conditioning with fludarabine and treosulfan in multiple myeloma patients, we performed a retrospective analysis including 34 patients who received this novel conditioning regimen between 2001 and 2005 in various centers in Germany and Finland (see the appendix). Primary end point of the analysis was to determine the feasibility. Secondary assessment end points included the time to engraftment, hematopoietic chimerism, acute and chronic graft-versus-host disease (GvHD), graft failure, toxicity, TRM and progression-free survival (PFS).
Patients and methods

Patients' characteristics
Patients' characteristics are depicted in Tables 1 and 2 . Treosulfan was given in a dose of 3 Â 10 g/m 2 to nine patients (26%), 3 Â 12 g/m 2 to 16 (47%) and 3 Â 14 g/m 2 to eight patients (24%). One patient (3%) received treosulfan in an incorrect dose by mistake and was, therefore, excluded from analyses referring to the post-transplant period. Antithymocyte globulin and alemtuzumab were incorporated in conditioning in 11 (32%) and two patients (6%), respectively. The median count of administered CD-34-positive cells was 5. Pretreatment of multiple myeloma before allogeneic SCT included melphalan-containing regimens in 33 of 34 patients (97%), anthracycline-based therapy in 31 (91%), thalidomide therapy in three (9%), bortezomib administration in seven (21%) and other treatment modalities (including administration of cyclophosphamide, ifosfamide, etoposide and bendamustin) in five patients (15%). Reasons for refraining from conventional conditioning included the patient's age in 13 cases (38%), intensive pretreatment in 14 (41%); 29 of 32 patients (91%) received previous ASCT (Table 1 ) and major concomitant disease in four cases (12%).
All multiple myeloma patients of the participating centers who received allogeneic SCT preceded by fludarabine/treosulfan conditioning between 2001 and 2005 were included in the analysis. Eleven of these multiple myeloma patients (32.5%) were selected out of a medac-sponsored prospective phase-II trial evaluating the feasibility of fludarabine/treosulfan conditioning before allogeneic SCT in patients with various hematological malignancies. This trial was also designed to explore dose escalation of treosulfan (3 Â 10, 3 Â 12 or 3 Â 14 g/m 2 , respectively). Twelve patients (35.0%) were analyzed in the context of a prospective, multicenter phase-II trial evaluating the feasibility and efficacy of fludarabine/treosulfan conditioning before allogeneic SCT in myeloma patients. All Patients included in this trial received 3 Â 12 g/m 2 treosulfan as conditioning therapy. Eleven patients (32.5%) were not included in one of these trials and analyzed retrospectively. ). In cases of unrelated donors, intravenous antithymocyte globulin (Fresenius, Bad Homburg, Germany) or alemtuzumab (Schering, Berlin, Germany) was added in doses of 10 mg/kg BW (day À4 to day À2) and 50 mg (total dose), respectively. Acute GvHD prophylaxis was cyclosporinebased in all patients. Cyclosporin was administered intravenously at a dose of 1.5 mg/kg BW every 12 h and adjusted to serum trough concentrations of 200-250 ng/ml. Cyclosporin was switched to oral application at the time of discharge and continued at full dosage until at least day þ 100. Thereafter it was tapered if severe GvHD did not occur. All patients received prophylaxis for bacterial, viral and fungal infections as well as pneumocystis carinii pneumonia according to local standards.
Assessment of engraftment, chimerism, GvHD and toxicity
The time of leukocyte engraftment was defined to be the first of three consecutive days with an absolute neutrophil /l, and that of platelet engraftment was defined as the first of three consecutive days with platelets X20 Â 10 9 /l without platelet transfusion. Chimerism analyses were based on the differentiation of donor and recipient alleles on short tandem repeats (STR) using the polymerase chain reaction (PCR) with fluorescence-labeled primers. Initial genotyping to detect informative STR loci was performed using EDTA peripheral blood (PB) from the patient and donor or graft. After transplantation, chimerism was analyzed on BM or PB samples on day þ 28 and day þ 100 followed by chimerism analysis according to local standards and clinical indication. Complete chimerism was defined as at least 95% donor cells and mixed chimerism as less than 95% donor cells.
Acute GvHD was evaluated in patients surviving for at least 25 days and graded according to the revised Glucksberg scale. 25 Chronic GvHD was assessed in patients with a survival or follow-up of at least 100 days and scored according to the revised Seattle criteria. 26 Toxicity was evaluated using the Common Toxicity Criteria (CTC, Version 2). Veno-occlusive disease (VOD) was classified according to the Jones criteria. 27 Definitions and statistical considerations The disease remission status and response were classified on an intent-to-treat basis, as published previously. 28 Patients with a survival or follow-up of at least 50 days after SCT were included in the response analysis. Treatment-related mortality was defined as any death after allogeneic SCT not caused by relapse or disease progression. Time to progression (TTP) was defined as the time from SCT to a more advanced stage of the disease or disease progression after transient remission (e.g., partial remission after CR). Progression-free survival was considered to be the time from SCT to death or disease progression/relapse. Overall survival (OS) was defined as the time from SCT to death or the last follow-up. Overall survival and PFS were calculated using the Kaplan-Meier method. The log-rank test (software SPSS 13.0 for WINDOWS XP) was used to compare the median PFS and OS referring to the administrated dose of treosulfan. P-values below 0.05 were considered significant (two-sided). Quoted confidence intervals (CI) refer to 95% boundaries. Calculation of the median follow-up was based on the time from SCT to the last follow-up for patients who were alive and from SCT to 10 January 2006, as the reference date for patients who had died.
Results
Engraftment kinetics and chimerism
All patients underwent myeloablation and all except one (97%) had platelets below 20 Â 10 9 /l in the post-transplant period. The median neutrophil and platelet nadir was reached on day þ 7 (range days 0-16) and day þ 8 (range days 4-25), respectively. Neutrophil engraftment occurred at a median of 13.5 days (range 7-24 days) in the total patient collective, whereas it took place at a median of 13 days (range 7-24 days) in those receiving PBSC and at a median of 18.5 days (range 13-19 days) in those receiving BM. Platelet engraftment was observed at a median of 13 days (range 8-33 days) in the total patient collective, whereas it occurred at a median of 12.5 days (range 8-21 days) in those receiving PBSC and at a median of 17 days (range 13-33 days) in those receiving BM. Primary neutrophil graft failure was not observed in any of the patients, whereas one patient (3%) showed a lack of platelet engraftment. Secondary graft failure was not observed in any of the patients.
On day þ 28, 94% of the patients (29 of 31) evidenced complete chimerism, whereas mixed chimerism was observed in two cases (6%). On day þ 100, complete chimerism was present in 19 of 23 patients (83%), whereas four patients (17%) showed mixed chimerism. Hematopoietic chimerism at least 1 year (range 366-1025 days) after SCT was analyzed in 10 patients and complete in all of them.
Graft-versus-host disease
Out of 33 patients 22 had acute GvHD with grade I in 11 (33%), grade II in 1 (3%), grade III in 7 (21%) and grade IV in 3 (9%) patients. Chronic GvHD was evaluable in 28 patients, 17 (61%) of whom showed no chronic GvHD, where as seven (25%) had limited disease and four (14%) had extensive disease. Treosulfan-based conditioning in multiple myeloma M Schmidt-Hieber et al
Toxicity and mortality analysis Non-hematological toxicities were limited and rarely exceeded CTC grade III (Table 3) . Grade III toxicities encompassed mainly fever in neutropenia and infections. Veno-occlusive disease was seen in one of 31 evaluable patients (3%), which resolved spontaneously. The TRM was 10% (three of 31 patients) on day þ 100 and 25% (6 of 24 patients) after 1 year ( Table 2 ). The estimated TRM 2 years after allogeneic SCT was 32% (Figure 1a) . Deaths caused by relapse occurred in 8% (two of 24 patients) in the first year after SCT and 9% (three of 33 patients) until the last follow-up (Table 2) . With a median follow-up of 708 days (range 60-1729 days) considering the total patient collective, the median OS has not yet been reached. The estimated OS at 1 and 2 years after SCT was 72 and 58%, respectively (Figure 1b) . The median OS has not yet been reached for the group of patients who received 3 Â 10 g/m 2 or 3 Â 12 g/m 2 treosulfan (not significant, P ¼ 0.66) and was 289 days for those who received 3 Â 14 g/m 2 (CI interval not applicable, not significant with respect to both other groups, P-values 0.38 and 0.44, respectively).
Response analysis
The remission status of the individual patients before and after allogeneic SCT is depicted in Table 2 . Before allogeneic SCT, CR was seen in three of 34 patients (9%), partial remission (PR) in 15 (44%), stable disease (SD) in two (6%) and minimal remission/response (MR) and plateau in one patient each (3%), whereas 12 (35%) had PD. The best response achieved after SCT was CR in 14 of 32 patients (44%), PR in 15 (47%), SD in two (6%) and MR in one patient (3%). At the last follow-up or before death, CR was seen in eight of 32 patients (25%), PR in four (13%), plateau in one patient (3%) and PD in 19 (59%). The median PFS including all patients was 180 days (CI 80-280 days), and the estimated PFS at 1 and 2 years after allogeneic SCT was 37% and 16%, respectively (Figure 1c) .
The median PFS was 240 days (CI 21-460 days) for patients who received 3 Â 10 g/m 2 treosulfan and differed not significantly from those who received 3 Â 12 g/m 2 (180 days, CI 103-257 days, P ¼ 0.53) or 3 Â 14 g/m 2 (210 days, CI 66-354 days, P ¼ 0.71), respectively.
Discussion
We investigated the novel conditioning regimen with treosulfan and fludarabine before allogeneic SCT in multiple myeloma patients considered to be ineligible for conventional conditioning. All patients underwent myeloablation and all except one had thrombocytopenia below 20 Â 10 9 /l. Stable neutrophil and platelet engraftment was achieved in 100 and 97%, respectively, with no cases of secondary graft rejection. Moreover, the rate of early complete hematopoietic donor/recipient chimerism was high at 94% and comparable to that found with conventional conditioning. In contrast to these observations, a variety of fludarabine-based RIC regimens used in multiple myeloma patients, including the incorporation of melphalan, busulfan or cyclophosphamide, were found to be associated with delayed engraftment, graft rejection or early mixed chimerism. 10, 15, 29 The stable engraftment and high rate of early complete chimerism achieved in our patient collective indicate that the conditioning agents fludarabine and treosulfan possess pronounced stem cell toxicity as well as immunosuppressive features, which have both been recently attributed to treosulfan in in vitro studies and rodent models. [30] [31] [32] [33] [34] [35] In contrast to busulfan, which preferentially depletes primitive stem cells, treosulfan was found to deplete committed progenitors as well as primitive stem cells in vitro. 31 In addition, agar colony assays demonstrated that the stem cell toxicity of treosulfan is superior to that achieved by busulfan or cyclophosphamide. 30 These in vitro data support the clearly higher rate of complete chimerism in our study as compared to the 36-80% found after fludarabine/busulfan conditioning. 12, [36] [37] [38] Early complete chimerism might be important in this setting, because the relapse rate was found to be higher for mixed than for complete chimerism in various diseases, including multiple myeloma. Treosulfan-based conditioning in multiple myeloma M Schmidt-Hieber et al
The favorable 100-day TRM of 10% found in our investigation was comparable to that observed using RIC protocols 5, 15, 41 and significantly lower than the TRM of up to 45% observed after conventional conditioning in multiple myeloma patients. [42] [43] [44] The conditioning-related nonhematological toxicities were limited and encompassed mainly fever and infections. Grade III liver toxicity occurred in 24% of our patients, whereas grade IV liver toxicity was not observed in any of them. A clearly more pronounced liver toxicity has been demonstrated after busulfan incorporation, even if the administered dose is lower in RIC than in conventional conditioning. Moreover, only one of our patients showed VOD, whereas liver toxicity is attributed to VOD in a major part of the patients who undergo busulfan conditioning. 12, 45 Acute grade II to IV and chronic GvHD rates were found in 33 and 39% of our patients, respectively. The rates of acute and chronic GvHD were comparable at 41 and 39%, respectively, in a recently published metaanalysis including 39 trials investigating RIC or toxicity-reduced conditioning regimens. 10 Ninety-four percent of our extensively pretreated multiple myeloma patients achieved disease remission after allogeneic SCT, 44% achieving transient or ongoing CR. Considering the limited median follow-up of 708 days and the small number of patients, the CR rate in our investigation seems to be in the range of that observed after conventional conditioning before allogeneic SCT. [42] [43] [44] Moreover, the CR rate seems to be superior to that of 25-35% observed after single ASCT or to that usually achieved by tandem ASCT. 46, 47 Moreover, our CR rate exceeds the 25% observed after allogeneic SCT in multiple myeloma patients using various RIC regimens, the majority of them containing either TBI, melphalan or busulfan in combination with fludarabine. 5 Though the transient remission rate was favorable, relapses or disease progression after SCT in the majority of our patients resulted in a median PFS of 180 days. However, although Crawley et al. 5 reported a slightly superior PFS in the trial they published in 2005, our estimated OS of 72 and 58% at 1 and 2 years was slightly superior to that described in their trial. These discrepancies might be partly owing to different strategies of response evaluation (e.g., first response evaluation at day þ 50 in our investigation and after day þ 100 in the trial conducted by Crawley et al.) . No significant difference of PFS or OS was found with respect to the administrated dose of treosulfan (3 Â 10, 3 Â 12 or 3 Â 14 g/m 2 , respectively). However, we cannot exclude that the limited number of patients in our investigation contribute to this observation.
We conclude that conditioning with fludarabine and treosulfan before allogeneic SCT is feasible in intensively pretreated multiple myeloma patients and is associated with stable engraftment, a high rate of complete chimerism and a low rate of graft rejection. Therefore, we assume, as previously suggested, 22 that fludarabine/treosulfan conditioning exhibits 'full-intensity' despite limited toxicity and should be discriminated from truly 'reduced-intensity' conditioning regimens.
Considering the extensive pretreatment of this patient cohort and the fact that a majority of patients showed disease progression before allogeneic SCT, the estimated OS of 58% at 2 years seems to be promising. The incorporation of novel agents (e.g., thalidomide, lenalidomide and bortezomib) in an algorithm of myeloma treatment as consolidation therapy after allogeneic SCT might be an interesting approach for further improvement of PFS and outcome.
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